IDH-specific vaccine for high-grade gliomas

IDH-specific vaccine for high-grade gliomas

VJOncology

1 year
493 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The NOA-16 trial is a multicenter, Phase I trial, which enrolled patients with newly diagnosed grade III and IV astrocytomas with specific IDH mutations. Here, Wolfgang Wick, MD, of the German Cancer Research Center, Heidelberg, Germany, speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, provides an overview of this trial, explaining how the IDH-specific vaccine tested will be integrated into the first-line treatment of these patients. The immunogenicity of the vaccine in the blood and tumors of the patients after treatment was assessed, and further investigations will now be carried out to detect the specific immune responses occuring when this treatment is combined with the immune checkpoint inhibitor avelumab.
Up Next Autoplay
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
5 Views
Cancer-News 14 hours
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 15 hours
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
7 Views
kidneycancer 17 hours
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
0 Views
kidneycancer 18 hours
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 1 day
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 1 day
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
7 Views
kidneycancer 2 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 2 days
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
Category: Kidney Cancer
7 Views
kidneycancer 3 days